EP4731770A1 - Protéines chimériques pour moduler l'activité d'un récepteur de cytokine - Google Patents

Protéines chimériques pour moduler l'activité d'un récepteur de cytokine

Info

Publication number
EP4731770A1
EP4731770A1 EP24737349.1A EP24737349A EP4731770A1 EP 4731770 A1 EP4731770 A1 EP 4731770A1 EP 24737349 A EP24737349 A EP 24737349A EP 4731770 A1 EP4731770 A1 EP 4731770A1
Authority
EP
European Patent Office
Prior art keywords
cytokine
isvd
sequence
chimeric protein
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24737349.1A
Other languages
German (de)
English (en)
Inventor
Pieter DESCHAGHT
Carlo Boutton
Hanne Van Gorp
Els Pardon
Jan Steyaert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vlaams Instituut voor Biotechnologie VIB
Ablynx NV
Vrije Universiteit Brussel VUB
Original Assignee
Vlaams Instituut voor Biotechnologie VIB
Ablynx NV
Vrije Universiteit Brussel VUB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlaams Instituut voor Biotechnologie VIB, Ablynx NV, Vrije Universiteit Brussel VUB filed Critical Vlaams Instituut voor Biotechnologie VIB
Publication of EP4731770A1 publication Critical patent/EP4731770A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)

Abstract

La présente invention appartient au domaine de l'immunologie et concerne des protéines et des polypeptides comprenant un domaine variable unique d'immunoglobuline (ISVD) fusionné avec une cytokine. Plus particulièrement, la présente invention concerne une protéine chimérique contenant un domaine variable unique d'immunoglobuline (ISVD) fusionné avec une cytokine, un site de fusion interne de l'ISVD étant lié à la cytokine, le site de fusion interne étant situé dans une boucle ou un virage entre deux éléments de structure secondaire. La fusion de la cytokine avec l'ISVD lors de la liaison avec le récepteur de la cytokine ou les sous-unités du récepteur permet de moduler l'activité du récepteur de la cytokine et/ou la signalisation en aval.
EP24737349.1A 2023-06-22 2024-06-21 Protéines chimériques pour moduler l'activité d'un récepteur de cytokine Pending EP4731770A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP23181005 2023-06-22
EP24168227 2024-04-03
PCT/EP2024/067427 WO2024261235A1 (fr) 2023-06-22 2024-06-21 Protéines chimériques pour moduler l'activité d'un récepteur de cytokine

Publications (1)

Publication Number Publication Date
EP4731770A1 true EP4731770A1 (fr) 2026-04-29

Family

ID=91758908

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24737349.1A Pending EP4731770A1 (fr) 2023-06-22 2024-06-21 Protéines chimériques pour moduler l'activité d'un récepteur de cytokine

Country Status (3)

Country Link
EP (1) EP4731770A1 (fr)
KR (1) KR20260028051A (fr)
WO (1) WO2024261235A1 (fr)

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB335768A (en) 1929-10-24 1930-10-02 Jacoviac Maurice Improvements in protecting devices for gramophone disc records
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
US5635599A (en) 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
EP0739981A1 (fr) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Fragments variables d'immunoglobulines-utilisation thérapeutique ou vétérinaire
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
DK1027439T3 (da) 1997-10-27 2010-05-10 Bac Ip Bv Multivalente antigenbindende proteiner
EP0967284A1 (fr) 1998-05-28 1999-12-29 Pfizer Limited Phosphodiestérases
CA2361678A1 (fr) 1999-02-05 2000-08-10 Rijksuniversiteit Leiden Methode de modulation de la biosynthese de metabolite dans des cellules recombinees
DE60035163T2 (de) 1999-03-15 2008-02-21 University Of British Columbia, Vancouver Abc1 polypeptide und verfahren und reagenzien zur modulation des cholesterolgehalts
CN100513570C (zh) 1999-06-18 2009-07-15 Cv治疗公司 结合框运输蛋白abc1的调节作用
IL147920A0 (en) 1999-08-02 2002-08-14 Keygene Nv Method for generating cgmmv resistant plants, genetic constructs, and the obtained cgmmv-resistant plants
GB9922124D0 (en) 1999-09-17 1999-11-17 Pfizer Ltd Phosphodiesterase enzymes
DE19955408A1 (de) 1999-11-18 2001-05-23 Bayer Ag GABA-B-Rezeptoren
BRPI0315666B8 (pt) 2002-10-23 2021-05-25 Ludwig Inst For Cancer Res Ltd dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos
WO2004041863A2 (fr) 2002-11-08 2004-05-21 Ablynx N.V. Anticorps a domaine unique diriges contre un interferon gamma et leurs utilisations
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
US8188223B2 (en) 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
AU2007237501A1 (en) 2006-04-14 2007-10-25 Ablynx N.V. DP-78-like nanobodies
WO2008020079A1 (fr) 2006-08-18 2008-02-21 Ablynx N.V. Séquences d'acides aminés dirigées contre l'il-6r et polypeptides les contenant utilisés pour le traitement de maladies et de troubles associés au signal médié par il-6
US20080267949A1 (en) 2006-12-05 2008-10-30 Ablynx N.V. Peptides capable of binding to serum proteins
CA2687903C (fr) 2007-05-24 2016-09-13 Ablynx N.V. Sequences d'acides amines dirigees contre rank-l et polypeptides comprenant ces dernieres, destines au traitement de maladies et affections osseuses
EP2650311A3 (fr) 2007-11-27 2014-06-04 Ablynx N.V. Séquences d'acides aminés dirigées contre des cytokines hétérodimériques et/ou leurs récepteurs et polypeptides les comprenant
WO2009127691A1 (fr) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capables de se lier à des protéines sériques et composés, constructions et polypeptides les comprenant
EP2531523A1 (fr) 2010-02-05 2012-12-12 Ablynx N.V. Peptides capables de se lier à la sérumalbumine, et composés, constructions, et polypeptides comprenant de tels peptides
SG10201805064SA (en) 2011-06-23 2018-07-30 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2723771B1 (fr) 2011-06-23 2019-09-11 Ablynx NV Protéines se liant à la sérumalbumine
EP4707303A2 (fr) 2014-05-16 2026-03-11 Ablynx NV Domaines variables d'immunoglobuline améliorés
LT3374392T (lt) 2015-11-13 2022-01-25 Ablynx Nv Patobulinti serumo albuminą surišantys imunoglobulino kintami domenai
AU2016357460B2 (en) 2015-11-18 2023-07-27 Ablynx Nv Improved serum albumin binders
RU2022101604A (ru) 2016-12-07 2022-03-29 Аблинкс Нв Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином
JP7219220B2 (ja) 2017-01-17 2023-02-07 アブリンクス エン．ヴェー． 改善された血清アルブミン結合剤
IL267897B2 (en) 2017-01-17 2025-02-01 Ablynx Nv Improved serum albumin binders
KR20200091400A (ko) 2017-10-31 2020-07-30 브이아이비 브이지더블유 신규한 항원-결합 키메라 단백질 및 이의 방법 및 용도

Also Published As

Publication number Publication date
KR20260028051A (ko) 2026-03-03
WO2024261235A1 (fr) 2024-12-26

Similar Documents

Publication Publication Date Title
US20240199740A1 (en) T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta
CA2691940C (fr) Methodes de fourniture de sequences d'immunoglobuline ameliorees
US12509522B2 (en) Polypeptides comprising immunoglobulin single variable domains targeting il-13 and OX40L
TWI619725B (zh) 趨化激素受體結合多肽
AU2007328900A1 (en) Peptides capable of binding to serum proteins
JP7657797B2 (ja) ＴＮＦαおよびＩＬ－２３を標的化する免疫グロブリン単一可変ドメインを含むポリペプチド
CN111108126B (zh) 血清白蛋白结合剂
CN117580865A (zh) Cd16抗体及其应用
IL293554A (en) Polypeptides comprising an immunoglobulin with one variable domain that target tnfa and ox40l
US20240368250A1 (en) Polypeptides binding to the neonatal fc receptor
US11098113B2 (en) Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
WO2024261235A1 (fr) Protéines chimériques pour moduler l'activité d'un récepteur de cytokine
TW202515916A (zh) 靶向pd-l1的免疫球蛋白單可變結構域
WO2025133166A1 (fr) Véhicules à base de protéines pour conjugaison d'amine spécifique à un site
RU2775063C2 (ru) Рекрутирующие т-клетки полипептиды, способные связывать cd123 и tcr альфа/бета
CN121986112A (en) Bivalent and multivalent albumin binders
WO2026052756A1 (fr) Domaines variables uniques d'immunoglobuline de liaison à her2, constructions les comprenant et leurs utilisations
CN121443644A (zh) 用于治疗IgG相关疾病和障碍的改善的FcRn拮抗剂

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20260120

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR